Fosmidomycin plus Clindamycin for Treatment of Pediatric Patients Aged 1 to 14 Years with <i>Plasmodium falciparum</i> Malaria
Steffen Borrmann(Heidelberg University), Peter G. Kremsner(Centre de Recherche Médicales de Lambaréné), Bénido Impouma(World Health Organization Regional Office for Africa), Jochen Wiesner, Sunny Oyakhirome(Albert Schweitzer Hospital), Pierre‐Blaise Matsiegui(Albert Schweitzer Hospital), Ayôla Akim Adégnika(Fondation pour la Recherche Stratégique), Saadou Issifou(Albert Schweitzer Hospital), Jürgen F. J. Kun(University of Tübingen), Ingrid Lundgren(St. Luke's Children's Hospital), Hassan Jomaa, David K. Hutchinson(Australian Antarctic Division)
Cited by 109
Related Papers
A Worldwide Map of<i>Plasmodium falciparum</i>K13-Propeller Polymorphisms
|New England Journal of Medicine|2016|574
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
|New England Journal of Medicine|2015|451
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
|Nature Communications|2021|295
The Eocene–Oligocene transition: a review of marine and terrestrial proxy data, models and model–data comparisons
|Climate of the past|2021|275
Fosmidomycin, a Novel Chemotherapeutic Agent for Malaria
|Antimicrobial Agents and Chemotherapy|2003|214